Study Phase 3

A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease

Trial Information

Generic NameGalantamineProduct NameRAZADYNE®Therapeutic AreaBehaviors and Mental DisordersEnrollment1063% FemaleN/A% WhiteN/A
Product ClassAlzheimer's Disease - Cholinesterase InhibitorsSponsor Protocol NumberGAL-INT-18Data PartnerJohnson & JohnsonCondition StudiedAlzheimer DiseaseMean/Median Age (Years)N/A

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.